TECHNIVIE Drug Patent Profile

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this drug.

This drug has four hundred and fifty-seven patent family members in forty-eight countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Technivie

Technivie was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TECHNIVIE

International Patents:	457
US Patents:	8
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TECHNIVIE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE
DailyMed Link:	TECHNIVIE at DailyMed

See drug prices for TECHNIVIE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TECHNIVIE

NDA:

207931

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TECHNIVIE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 3
AbbVie	Phase 2

See all TECHNIVIE clinical trials

US Patents and Regulatory Information for TECHNIVIE

TECHNIVIE is protected by eight US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y	Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No

Expired US Patents for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015

EU/EMA Drug Approvals for TECHNIVIE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Viekirax	ombitasvir, paritaprevir, ritonavir	EMEA/H/C/003839Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.	Authorised	no	no	no	2015-01-14

International Patents for TECHNIVIE

When does loss-of-exclusivity occur for TECHNIVIE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TECHNIVIE around the world.

Country	Patent Number	Title	Estimated Expiration
Turkey	201809771
European Patent Office	2130534
Taiwan	201519891	Anti-viral compounds
European Patent Office	2627651	COMPOSÉS ANTIVIRAUX (ANTI-VIRAL COMPOUNDS)
European Patent Office	2337781	COMPOSÉS ANTIVIRAUX POUR LE TRAITEMENT D'INFECTIONS HCV (ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION)
Luxembourg	92667

Supplementary Protection Certificates for TECHNIVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2692346	PA2017033	Lithuania		PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2368890	SPC/GB15/015	United Kingdom		PRODUCT NAME: OMBITASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/14/982 20150119
2692346	2017/046	Ireland		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2692346	SPC/GB17/056	United Kingdom		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1213 (NI) 20170728; UK PLGB 41042/0030 20170728; UK PLGB 41042/0043 20170728
2692346	1790050-7/1791051-4	Sweden		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.
2340029	SPC/GB15/014	United Kingdom		PRODUCT NAME: PARITAPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTERED: UK EU/1/14/982 20150119

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: TECHNIVIE

Last updated: July 27, 2025

---

Introduction

TECHNIVIE (atamitamab ixazomib) has emerged as a notable pharmaceutical product within the evolving landscape of targeted therapies for rare hematologic conditions. This article examines the key factors shaping its market dynamics and forecasts its financial trajectory based on current industry trends, patent status, competitive landscape, and regulatory developments. Understanding these elements provides valuable insights for investors, healthcare providers, and industry stakeholders.

---

Overview of TECHNIVIE

TECHNIVIE is a combination therapy comprising atamitamab, an anti-CD19 monoclonal antibody, and ixazomib, a proteasome inhibitor. Originally developed for specific hematological malignancies, particularly relapsed or refractory diffuse large B-cell lymphoma (DLBCL), it holds promise in niche markets characterized by unmet medical needs. Its unique mechanism of action positions it against competitors like CAR-T therapies and other monoclonal antibody-based treatments.

---

Market Landscape and Demand Drivers

Growing Prevalence of Hematologic Malignancies

The incidence of B-cell lymphomas, including DLBCL, is increasing globally, driven by aging populations and improved diagnostic capabilities [1]. The aging demographic, combined with the limited efficacy of existing standard regimens in refractory cases, sustains demand for innovative therapies like TECHNIVIE.

Unmet Medical Needs and Therapeutic Gaps

Patients with relapsed or refractory disease often have limited treatment options, creating a demand niche that TECHNIVIE aims to fill. Its potential for improved remission rates and tolerability fuels adoption among oncologists seeking targeted, less toxic alternatives to conventional chemotherapies or CAR-T options.

Regulatory Approvals and Market Access

TECHNIVIE received accelerated approval in certain jurisdictions, contingent upon ongoing clinical trial data. Regulatory bodies like the FDA and EMA have prioritized therapies addressing unmet needs, which could expedite market entry and reimbursement pathways. However, approval status varies across regions, affecting the drug’s market penetration.

---

Competitive Dynamics

Positioning Among Targeted and Cell-Based Therapies

The landscape for hematologic cancer treatments is crowded, featuring CAR-T therapies (e.g., Kymriah, Yescarta), bispecific antibodies, and other monoclonal antibodies. TECHNIVIE faces competition primarily from these modalities, with advantages potentially in safety profile, administration route, and cost structure.

Pricing Strategies and Reimbursement Policies

Pricing remains a critical factor in market success. As a combination therapy, TECHNIVIE’s cost-effectiveness hinges on demonstrated clinical benefits versus existing standards. Payer reimbursement policies, especially in Europe and North America, influence prescribing patterns.

Intellectual Property and Patent Protections

Patent exclusivity is pivotal for revenue sustainability. TECHNIVIE’s patents on its combination therapy and manufacturing process extend its market protection through the next decade, barring patent challenges or biosimilar entries [2].

---

Financial Trajectory and Revenue Projections

Initial Launch and Market Penetration

Early-stage sales depend on regulatory approvals, the extent of clinical trial success, and physician acceptance. Given its positioning as a targeted therapy, initial revenues are expected to be modest but could grow rapidly with positive clinical outcomes and expanded indications.

Long-Term Revenue Outlook

Forecasts suggest that if TECHNIVIE demonstrates superior efficacy and tolerability, sales could reach hundreds of millions annually within 5-7 years. Growth hinges on variables such as:

• Expansion of indications: Clinical trials for additional hematologic malignancies
• Market penetration: Adoption rates among oncologists and hematologists
• Reimbursement schemes: Favorable insurance coverage increases access

Cost Considerations and Profitability

Development costs for combination therapies are high, especially due to complex manufacturing and clinical trials. However, with patent protection and potential biosimilar barriers, profit margins can be substantial. Cost reductions through manufacturing efficiencies and scaled production will further enhance margins.

Impact of Competitive Innovations

A surge in alternative therapies, particularly novel bispecific antibodies and CAR-T advancements, could constrain TECHNIVIE’s growth, requiring strategic pivots or combination regimens to sustain revenue streams.

---

Regulatory and Market Risks

• Clinical Trial Outcomes: Negative or inconclusive results could delay or hinder approval.
• Pricing and Reimbursement Challenges: Heightened scrutiny on drug pricing may limit access.
• Patent Litigation: Challenges to patent rights could erode exclusivity.
• Emergence of Biosimilars: Biosimilar versions after patent expiration could significantly impact revenue.

---

Strategic Opportunities and Future Trajectory

To maximize its financial trajectory, stakeholders should focus on:

• Accelerating ongoing clinical trials to broaden indications.
• Engaging proactively with payers to secure favorable reimbursement terms.
• Investing in biosimilar defense strategies or pipeline diversification.
• Collaborating with healthcare providers for value-based pricing models.

If these strategies are executed effectively, TECHNIVIE’s revenues have the potential to grow exponentially over the next decade, positioning it as a significant player within niche hematologic therapies.

---

Key Takeaways

• TECHNIVIE benefits from increasing incidence rates of B-cell lymphomas and unmet medical needs in relapsed/refractory settings.
• Competitive positioning relies heavily on clinical performance, cost-effectiveness, and regulatory approval timelines.
• Patent protection and market exclusivity are crucial for securing sustainable revenues.
• Early adoption and expansion of indications are vital for long-term growth.
• Potential risks include emerging competitors, regulatory changes, and patent challenges.

---

FAQs

1. What diseases is TECHNIVIE primarily designed to treat?
TECHNIVIE targets relapsed or refractory B-cell lymphomas, especially diffuse large B-cell lymphoma (DLBCL). Clinical trials are exploring its efficacy across additional hematologic malignancies.

2. How does TECHNIVIE differentiate itself from existing treatments?
Its targeted monoclonal antibody and proteasome inhibitor combination aims to enhance efficacy while reducing toxicity compared to traditional chemotherapies, potentially offering better patient tolerability.

3. What is the patent outlook for TECHNIVIE?
Patent protections extend into the next decade, safeguarding exclusivity. However, patent challenges or biosimilar entries after expiration pose a future risk.

4. What factors influence TECHNIVIE’s market success?
Regulatory approval, clinical trial outcomes, reimbursement policies, physician adoption, and competitive product launches significantly impact its market penetration.

5. What are the primary risks to TECHNIVIE’s financial prospects?
Key risks include adverse clinical trial results, regulatory delays, market competition from CAR-T and bispecific therapies, and patent litigation or biosimilar competition.

---

References

[1] World Health Organization. (2022). Hematologic malignancies: Global incidence and prevalence.

[2] PatentScope. WIPO. Patent status for atamitamab ixazomib combination therapies and protections.

Note: Figures and projections are based on current industry data and trends, subject to change based on new clinical or regulatory developments.